MindMed just started a Phase 1 trial which is studying the effects of LSD + MDMA administered together.
Seventeen 4-acetoxy and 4-hydroxy substituted derivatives “have psilocybin-like pharmacological properties.”
“We have some [compounds] now that are unlike anything you’ve ever seen before.”
Patent filings indicate that CaaMTech was the first company to propose an entourage effect in psychedelic compounds.
This company is approaching psychedelic mushroom research literally from the ground up.
Leading scientists continue to remove roadblocks by developing methods for synthesizing psychedelic compounds for further research.
“I believe one person can produce enough 5-MeO-DMT to supply everyone that would ever want it.”
Changes in brain functioning, new synthesis methods, and psychotherapy dominate this year’s most-cited psilocybin papers.
This study provides meaningful access to some lesser-known magic mushroom compounds and conducts biological testing on them for the first time.
This influential study advances the understanding of magic mushroom physiology and helps answer several fundamental questions.